Cyrus Reed: Iris, I went to visit my uncle last month — he's 71, sharp as anything mentally, but he can barely get out of a chair without help. And I keep thinking about that visit because I read this piece in Scroll.in by Stuart Phillips and it made me realize — my uncle is basically the WHO data made personal.
Iris Holm: The 9.5-year gap.
Cyrus Reed: Exactly that — wait, you've already read it?
Iris Holm: WHO World Health Statistics 2024. Global life expectancy in 2021: 71.4 years. Healthy life expectancy: 61.9. Nearly a decade of your life, on average, spent in less than full health. That's the number Phillips is building his whole argument on.
Cyrus Reed: And he's a kinesiology professor at McMaster — so this isn't some wellness blogger, this is a Tier 1 Canada Research Chair saying: the goal shouldn't be living longer, it should be living well longer. Healthspan over lifespan. But here's what I couldn't work out — his ingredients are exercise, sleep, diet, social connection, not smoking, limiting alcohol. That's not a revelation. My doctor has been saying that for fifteen years.
Iris Holm: Right. So what is new? That's the question. Is Phillips advancing the science or reframing the same public health consensus with a sharper word — healthspan — and publishing it in Scroll.in instead of a journal?
Cyrus Reed: No but — I think the frame might actually be doing work, even if the ingredients aren't new. Because lifespan is easy to measure. You either died or you didn't. Healthspan is — how do you even count that?
Iris Holm: That's the tension I want to sit with. Whether the reframe actually shifts anything — policy, capital, behavior — or whether it's just language that makes us feel like we're doing something different while we keep doing the same thing.
Cyrus Reed: But that's — okay, that's actually the thing that breaks me open on this. Because ARK Invest published analysis saying the most immediate, broadly accessible longevity interventions are behavioral. Diet, exercise, sleep. Not a moonshot. Not a clinical trial. The answer is already sitting there and we're — wait, so why isn't that where the money goes?
Iris Holm: Because you can't patent a walk.
Cyrus Reed: No but — huh. Okay so L.E.K. Consulting tracked longevity biotech funding at $8.5 billion across 331 deals in 2024. That's more than double what went in the year before. And Al Jazeera flagged $3.74 billion just in Q1 2026 alone. One quarter.
Iris Holm: And the clinical trials are still early-stage. Al Jazeera's piece — September 27th — says it could be decades before we actually know if any of it works.
Cyrus Reed: So the gut-punch version of this — and tell me if I'm getting this right — is that at the ARDD conference, October 2026, at Harvard, someone stood up and showed poster research: 80% symptom burden among women in hormonal transition. Treatment rate under 5%. That's not a mystery disease. That's a known, visible, fixable gap.
Iris Holm: Eighty percent. Under five. While the room was also discussing billion-dollar therapeutics pipelines.
Cyrus Reed: Which is — wait, is that a competing capital problem or are these genuinely separate pools that never touch? Because Phillips is making it sound like a choice, but maybe Eli Lilly's CVC arm and, I don't know, a municipal public health budget are just — they're not fishing in the same pond at all?
Iris Holm: That's exactly where the framing gets slippery. If the pools don't compete, Phillips's resource argument collapses into rhetoric. But the second-order consequence is the same regardless — public health loses its claim on *urgency* because we've decided the biotech story is the interesting one.
Cyrus Reed: So morbidity compression — actually shortening the diseased tail — just becomes unfundable because it's boring to pitch?
Iris Holm: Not unfundable. Unfashionable. And that distinction is where Phillips's argument actually has teeth — because look at what *is* fashionable. Sam Altman writes a $180 million seed check into Retro Biosciences in April 2022. One check. Seed round. Forbes calls longevity biotech 'the billionaire's next big bet after AI.' That's not capital allocation. That's narrative gravity.
Cyrus Reed: Wait — $180 million seed? Like, that's not a Series B, that's the *first* round?
Iris Holm: Seed. And then Eli Lilly moves in — nearly half of major longevity biotech BD and CVC deals from January 2025 through August 2026 involve them. So now you have billionaire prestige capital and Big Pharma signaling simultaneously. That's a legitimacy loop. And L.E.K. projects 2026 financing at 55 to 60 percent above 2025 already.
Cyrus Reed: But — okay, I want to push on your earlier point, because I think there's a version of this where Phillips is actually attacking the wrong thing. Like, Sam Altman's $180 million wasn't going to a community health worker program *anyway*, right? So is the competition even real?
Iris Holm: That's the structural weak spot. And frankly, Phillips doesn't address it cleanly. The pools don't compete directly — venture capital has a different risk profile, different time horizon than a municipal health budget. So his resource argument is — I mean, it's not *wrong*, but it's not quite the argument he's making.
Cyrus Reed: So what's the *actual* argument then?
Iris Holm: Political economy. When Al Jazeera runs a piece September 27th saying these trials will take *decades* to prove out — and the money's still accelerating — what that does is shift where *urgency* lives. Congress doesn't fund boring. City councils don't fund boring. Phillips is making a legitimacy argument dressed as a budget argument, and that's why it lands soft.
Cyrus Reed: Huh — so the real harm isn't that Retro Biosciences exists, it's that Retro Biosciences makes the *other* conversation feel solved? Or small?
Iris Holm: And the equity dimension of that — who gets left out when we decide the biotech story is the interesting one — that's actually where this whole thing breaks open. We'll get there.
Cyrus Reed: But left out *when* — that's the part that keeps nagging me. Because Phillips isn't just saying who gets left out, he's saying it's already too late by the time the biotech arrives. Like, the UN projects 65-plus population hitting 1.6 billion by 2050 — up from 761 million in 2021 — that's more than doubling in under thirty years. And no pipeline of longevity drugs reaches those people in time, right? They're already old.
Iris Holm: That's the life-course argument. Health at 72 was determined at 42. At 22. At 12, frankly.
Cyrus Reed: So Phillips is saying — and this is where I think I finally get it — nutrition, housing, working conditions, income, access to preventive care. The social determinants. Those aren't background noise, they're the actual mechanism.
Iris Holm: And the WHO's definition doesn't help the biotech case here. Healthy aging is — their exact framing is — developing and maintaining *functional ability* that enables well-being. Not biological markers. Not telomere length. Function.
Cyrus Reed: Okay wait — so picture this. A woman, 62, somewhere in a low-income neighborhood. Employed, insured, no diagnosis. She knows exercise matters, she's heard it her whole life. But her block has no safe sidewalk. It's dark at 5 a.m. when she leaves for work. The gym costs sixty bucks a month she doesn't have. What does the Retro Biosciences pipeline give her?
Iris Holm: Nothing actionable for a decade at minimum. And that's — actually, I'll grant this. The equity timing argument holds. That scenario is a real policy failure, not a rhetorical one.
Cyrus Reed: That's — wait, you're giving him that?
Iris Holm: On the life-course framing, yes. But Didier Coeurnelle at Heales is presenting at ARDD 2026 arguing radical life extension is moving into mainstream scientific discourse — and that cultural momentum is exactly what makes Phillips's case harder to land politically. The biotech narrative is *winning*. Partial credit doesn't change that.
Cyrus Reed: But winning narratively — does that actually move policy? Because the Global Healthspan Policy Institute exists, the framing is spreading, Phillips gets published in Scroll.in and people are reading it. So at some point does the word 'healthspan' start doing political work, or is it just — wait, is it just giving the longevity biotech sector a better brand?
Iris Holm: That's the only test that matters by 2030. Not whether Phillips is right about the science — the social determinants argument has a decades-long literature, he's not breaking new ground there. The Scroll.in piece is news because of the reframe and the discussion it generated. The empirical question — who actually receives investment by 2030 and who gets left behind — that one hasn't run yet.
Cyrus Reed: Huh. And we genuinely don't know.
Iris Holm: No. We don't. That's — I mean, that's actually where I land. Does the word healthspan move money toward the 62-year-old with no sidewalk, or does it just make the Retro Biosciences pitch deck sound more equitable? I can't answer that. Nobody can yet.
Cyrus Reed: That's a genuinely uncomfortable place to stop.
